Senolytics · fisetin
Fisetin benefits: the mouse study everyone cites, and the retest nobody does
The fisetin benefits you read about trace back to one 2018 mouse paper, and 5 years later, in 2023, the multi-site program built to catch irreproducible results retested the compound and found no lifespan extension.
Where did fisetin's reputation come from?
Limited evidence From one mouse study published 5 years before the 2023 retest. That 2018 study screened ten flavonoids for senolytic activity, found fisetin the most potent, and reported that acute or intermittent treatment of progeroid and aged mice improved healthspan and lifespan.[1] Almost every list of fisetin benefits since traces back to it.
The target is real
Senescent cells accumulate with age, stop dividing without dying, and release inflammatory signals that disturb surrounding tissue.[2] Their buildup sits in the current consensus framework of how organisms age, and clearing them genetically improves function in aged mice.[3]
So the fisetin senolytic hypothesis was never fringe. It attached a cheap, food-derived molecule to one of the best-supported targets in the field, which is exactly why the result traveled so fast and so far beyond the paper.
Did fisetin extend lifespan when it was retested?
No. When the NIA Interventions Testing Program retested fisetin in 2023, it did not produce a lifespan extension.[4] The program exists because single-laboratory lifespan results frequently fail to replicate, and it tests compounds in genetically heterogeneous mice at multiple independent sites.
It has killed many promising candidates, and fisetin joined them. That result is the single most decision-relevant fact about this compound, and it appears on essentially none of the pages selling it. A striking result from one lab, followed by a null result from the program designed to check such results, is a specific and familiar pattern.
Show the numbers as a table
| Measure | Value |
|---|---|
| Extended male lifespan | 2 compounds |
| No extension (incl. fisetin) | 4 compounds |
What a null retest does and does not settle
A null result in the program does not prove fisetin is inert. It shows that the dose and schedule tested did not lengthen life in mice bred to resemble a varied population, across independent sites.[4]
It does shift the burden of proof. Anyone claiming fisetin extends life now has to explain why the stricter test disagreed with the original screen.
We thought we were testing the notion that removing senescent cells would be good for you, and it turned out we were testing the notion that fisetin removes senescent cells.
Why the retest outweighs the original screen
The 2018 screen was one laboratory's result. The 2023 retest ran at independent sites in mice bred to resemble a varied population, which is the design built to catch results that do not travel.
When the two disagree, the stricter design is the one to weight, while remembering it tested one dose and delivery method.
Has fisetin been tested in humans?
Not in any trial showing benefit, since the human work used dasatinib with quercetin, which in old mice improved physical function and late-life survival.[5] The first human report followed: in people with diabetic kidney disease, 3 days of the combination (per the 2019 Hickson trial) reduced senescent cell burden in fat tissue.[6]
Those trials involved a handful of patients each, used a chemotherapy drug alongside a flavonoid, and measured markers or short-term function rather than health outcomes. Quercetin's own evidence summary describes a compound with poor bioavailability and modest effects.[7] None of this transfers to a fisetin capsule.
Does oral fisetin reach the tissues that matter?
Nobody has shown that it does. Fisetin is poorly water-soluble and poorly absorbed, which supplement pages acknowledge when recommending fat-paired or liposomal formulations. The acknowledgment is honest and the conclusion drawn from it usually is not.
This matters for anyone weighing fisetin benefits against cost. Improving absorption from very low to slightly less low does not establish that a human achieves the tissue concentrations that produced the mouse results. That is the step the whole product category assumes and nobody has demonstrated.
What are the proven fisetin benefits today?
In people, none yet. What exists is a mouse healthspan and lifespan result that a stricter program did not reproduce, laboratory evidence of antioxidant and anti-inflammatory activity, and preclinical neuroprotection data.
| Study | Subjects | What it found |
|---|---|---|
| Yousefzadeh 2018 | Progeroid and aged mice | Most potent of ten flavonoids; healthspan and lifespan improved[1] |
| Harrison 2023 (ITP) | Genetically heterogeneous mice, multiple sites | No lifespan extension[4] |
| Hickson 2019 | People with diabetic kidney disease | 3 days of dasatinib with quercetin, not fisetin, lowered senescent cell burden[6] |
That is not nothing. It is a legitimate research compound with a plausible mechanism. It is also a considerable distance from what the supplement pages describe, and the gap is filled with mouse data presented without the species attached.
Show the numbers as a table
| When | Event | Detail |
|---|---|---|
| 2018 | D+Q mouse study | Function and survival |
| 2018 | Fisetin screen | Top of 10 flavonoids |
| 2019 | Senescence consensus | Definition agreed |
| 2019 | First human report | D+Q, not fisetin |
| 2023 | ITP retest | No lifespan extension |
Is the senolytic idea still worth taking seriously?
Yes, as long as you separate the idea from the compound. Senolytics are one of the more compelling concepts in aging biology, supported by genetic experiments that removed senescent cells and improved outcomes in mice.
If any intervention in this field works, this class is a reasonable candidate.
The compound is a separate question
Whether fisetin at an achievable oral dose is that intervention is a different question, and current evidence points away from it. Our review of the senolytic evidence covers the class properly, and the dosing page covers the intermittent protocols in circulation.
Is it worth taking fisetin?
Not on current evidence, though it is cheap and apparently well tolerated. It is mechanistically interesting and unproven in people, with a failed lifespan retest behind it. If you take it, take it knowing that, rather than on the strength of a benefits list built from mouse data.
- Skip it during pregnancy or breastfeeding, where the evidence is simply absent.
- Ask first if you take anticoagulants or other prescription medication, since flavonoids can affect platelet function and interaction data are thin.
Fisetin is a flavonol found mainly in strawberries, with smaller amounts in apples, persimmons, onions and grapes. Eating them is not a substitute and it is not worthless either, since the dietary pattern that contains them has better evidence than the capsule does.
Where to go next
If the realistic fisetin benefits look thinner than the label suggested, that is the evidence speaking, not a verdict on the whole field. Our review of the wider supplement evidence ranks fisetin against the alternatives on exactly this standard.
Frequently asked questions
What are the benefits of fisetin?
In mice, senescent cell clearance with improvements in healthspan and lifespan. In cells, antioxidant and anti-inflammatory activity. In humans, essentially nothing has been demonstrated yet, and the rigorous mouse lifespan program that retested it did not reproduce the lifespan result.
Does fisetin actually work in humans?
Unknown. Small human trials of senolytic protocols exist, mostly using dasatinib with quercetin rather than fisetin, and they measured senescent cell markers rather than clinical outcomes. No trial has shown a health benefit from fisetin in people.
How long does it take for fisetin to work?
The question assumes a measurable effect. Senolytic protocols are dosed intermittently on the reasoning that clearing senescent cells is an occasional event rather than a daily one, and there is no accessible test to tell you whether anything happened.
Do the human senolytic trials involve fisetin at all?
No trial showing a benefit used it. The first human report, in people with diabetic kidney disease, gave dasatinib with quercetin for 3 days and found lower senescent cell burden in fat tissue. That is a different pair of compounds, and a marker rather than a health outcome.
Can anyone tell whether a fisetin course worked?
Not outside a research setting. Trials count senescent cells in tissue samples, which no consumer test offers, and no validated blood marker tracks them. A person taking an intermittent course has no accessible way to confirm that anything was cleared.
Where do the high intermittent doses come from?
From mouse experiments, not human trials. The founding study gave fisetin to progeroid and aged mice, and circulating protocols translate those doses to human body weight, an extrapolation no trial has tested for benefit or for long-term safety in healthy people.
Can you take too much fisetin?
No upper limit has been established. Reported tolerability is good at supplement doses, and the senolytic protocols in circulation use high intermittent amounts that have not been tested for long-term safety in healthy people.
Is fisetin better than quercetin?
In the founding screen, fisetin was the most potent senolytic of ten flavonoids tested, which is where its reputation comes from. Quercetin has more human trial exposure, mostly in combination with dasatinib. Neither has a clinical outcome behind it.
Did fisetin extend lifespan in the ITP?
No, and this is the most important fact about it. The Interventions Testing Program, which tests compounds across multiple independent sites specifically to catch irreproducible results, did not find a lifespan extension with fisetin.
Why is it still popular then?
Because the original mouse result was striking, the mechanism is attached to a genuine hallmark of aging, and the compound is cheap, natural-sounding and unregulated. None of those is evidence that it works in people.
What is a senolytic anyway?
A compound that selectively kills senescent cells, which are damaged cells that stop dividing but do not die and release inflammatory signals. Their accumulation is a recognized hallmark of aging, and clearing them improves function in aged mice.
Is the senolytic idea itself sound?
The idea is among the best in the field, supported by genetic mouse experiments where clearing senescent cells improved healthspan. The uncertainty is entirely about whether any available compound does that safely and effectively in humans.
Are there human senolytic trials?
Yes, small ones. A pilot in idiopathic pulmonary fibrosis reported improved physical function measures, and a study in diabetic kidney disease reported reduced senescent cell burden in tissue. Both used dasatinib with quercetin, both were tiny, and neither was a fisetin trial.
What would change the picture for fisetin?
A human trial showing that a tolerable dose reduces senescent cell burden and improves a clinical outcome. Trials are running. Until they report, fisetin benefits in humans remain an extrapolation from a mouse study that a stricter program did not reproduce.
References
7 sources, all link-checked; oldest check
- Fisetin is a senotherapeutic that extends health and lifespan. Yousefzadeh MJ et al. EBioMedicine 2018;36:18–28.Publisher blocks automated checks · last tried Sep 15, 2026
- Astaxanthin and meclizine extend lifespan in UM-HET3 male mice; fisetin, SG1002, dimethyl fumarate and mycophenolic acid do not. Harrison DE et al. GeroScience 2023 (NIA Interventions Testing Program; cited 64).The most rigorous multi-site mouse lifespan program tested fisetin and found no lifespan extension.Verified Sep 15, 2026
- Senolytics decrease senescent cells in humans: preliminary report from a clinical trial of dasatinib plus quercetin. Hickson LJ et al. EBioMedicine 2019;47:446–456.Small first-in-human senolytic trial.Publisher blocks automated checks · last tried Sep 15, 2026
- Senolytics improve physical function and increase lifespan in old age. Xu M et al. Nature Medicine 2018;24:1246–1256.Verified Sep 15, 2026
- Quercetin: evidence summary. Examine.com.Publisher blocks automated checks · last tried Sep 15, 2026
- Cellular senescence: defining a path forward. Gorgoulis V et al. Cell 2019 (cited 3,603).Consensus definition: a cell state triggered by stressful insults and certain physiological processes, with prolonged and generally irreversible cell-cycle arrest, secretory features, macromolecular damage and altered metabolism.Publisher blocks automated checks · last tried Sep 15, 2026
- Hallmarks of aging: an expanding universe. López-Otín C et al. Cell 2023;186(2):243–278.Updated framework: twelve hallmarks.Publisher blocks automated checks · last tried Sep 15, 2026
Every link above is re-requested on a schedule by an automated checker; the date shown is when it last answered. Publishers that block automated requests are marked as such rather than reported broken. Our editorial standards explain how a source gets cited here in the first place.
Filed by the Rapamycin.store evidence desk. Each source is re-checked when the page is reviewed.
Own a longevity or health brand?
Rapamycin.store publishes sponsored and guest posts on an aged, topically-relevant domain, and offers display advertising. Tell us what you want to promote and we'll send our current options.